Aim Immunotech Stock News

Ampligen ® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center Treatment with Ampligen following FOLFIRINOX was…

Ampligen® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Eras

Ampligen ® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center

AIM ImmunoTech (AIM) announces strategic sale of its facility located in New Brunswick, New Jersey for a purchase price of $3.9M.The Company will retain access to space in…

OCALA, Fla., March 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therape

AIM ImmunoTech (AIM) has announced the appointment of Robert Dickey IV, as its Chief Financial Officer.Effective April 4, 2022, Mr

Industry veteran and financial and strategic leader with deep capital markets and business development transactional expertise across life science and medical device companies Industry veteran and fin

AIM ImmunoTech Inc (NYSE:AIM) has announced the appointment of Robert Dickey IV, as its chief financial officer (CFO).  Effective April 4, 2022, AIM ImmunoTech said, Dickey will become CFO and curr

AIM ImmunoTech management to participate in webinar Thursday, January 27th from 2:00 pm - 3:00 pm ET

AIM ImmunoTech <> announced positive data from a phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer.The phase 1/2 study, which is

Chemokine-modulating IP chemo-immunotherapy combination demonstrated to be well tolerated, and associated with interferon stimulated gene changes that favor cytotoxic T lymphocytes chemoattraction and function Strength of data support advancement into Phase 2 clinical study Phase 2 study will be conducted to evaluate immunologic and clinical efficacy of tumor loaded αDC1 vaccine in conjunction with the cisplatin/chemokine modulatory combination regimen OCALA, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: AMERICAN ) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the publication of positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer. The manuscript titled, " Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity 1 " was published in the American Association for Cancer Research publication, Clinical Cancer Research .

AIM ImmunoTech Inc (NYSE:AIM) announced positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer.  The study has been published in the American

Live video webcast presentation on Wednesday, January 26th at 10:00 AM ET Live video webcast presentation on Wednesday, January 26th at 10:00 AM ET